Evidence & record
The record, stated plainly.
Granted patents in three jurisdictions, the published research beneath them, and an honest account of what that record establishes and what it does not.
Five grants, three jurisdictions.
Each of these is a granted patent held by ReeLabs, not an application. Every number below links to the public register, so you can read the claims rather than take our description of them.
18 August 2020
Foetal polymix of mesenchymal stem cells under hypoxic conditions for the treatment of clinical disorders and diseases
Core to the protocol27 July 2021
Foetal polymix of mesenchymal stem cells under hypoxic conditions for the treatment of clinical disorders
Core to the protocol21 April 2021
25 February 2025
The method of autologous primary hair follicles preparation in 3D culture
3 August 2023
Seven completed. Three running.
Nineteen papers, and what they cover.
The published work of the laboratory behind the protocol. Each entry links to the paper itself.
Work carried out in patients, published in peer-reviewed journals.
Phase 1 clinical trial for intravenous administration of mesenchymal stem cells derived from umbilical cord and placenta in patients with moderate Covid-19 virus pneumonia
American Journal of Stem CellsConvalescent plasma to limit coronavirus associated complications: a proof of concept phase-2 clinical study
Journal of Current Medical Research and OpinionSafety and efficacy of a combination therapy in Duchenne muscular dystrophy patients
Journal of Embryology & Stem Cell ResearchRetrospective analysis of autologous bone marrow derived mononuclear stem cells in degenerative arthritis of the knee
Journal of Stem Cell Research & TherapeuticsCell characterisation, expansion and banking method.
A mixture of mesenchymal stem cells from perinatal sources supports consistent ex-vivo CD34+ haematopoietic stem cell expansion
International Journal of Life Sciences ResearchHuman adult stem cells maintain a constant phenotype profile irrespective of their origin, basal media, and long term cultures
Hindawi Publishing CorporationStrategies to make cord blood banking more meaningful
International Journal for Scientific Research & DevelopmentConducted at PGIMER, Chandigarh.
Contributions to the regenerative medicine literature.
Bone marrow versus dental pulp stem cells in osteogenesis
Kanafi, Ganneru, Marappagounder, Behera & BhondeAdipose-derived stem cells in musculoskeletal disorders
Marappagounder, Kotturu, Behera, Ajumeera & RajappaStem cells of human endometrium: trash to treasure
Somasundaram, Marappagounder, Venkatesan, Behera & BhondeRedundant human omentum fat: a leap towards regenerative medicine
Indumathi, Harikrishnan & DhanasekaranSubcutaneous adipose tissue-derived stem cells: advancement and applications in regenerative medicine
Indumathi, Mishra, Harikrishnan & DhanasekaranBehaviour of human mesenchymal stem cells on calcium phosphosilicate scaffolds for bone tissue engineering
European Federation of PeriodontologyRead this part
What this record establishes — and what it does not.
The patents cover the cell-processing methods the Golden Vial protocol is built on. Two of them — the foetal polymix of mesenchymal stem cells under hypoxic conditions, granted in both the United States and Europe — describe the preparation at the centre of the programme. Those are the strongest documents on this page, and they are public.
The published papers are a different thing, and we would rather say so than let the length of the list do the arguing. They document two decades of ReeLabs work in regenerative medicine: limb ischaemia, Covid-19 pneumonia, muscular dystrophy, degenerative arthritis of the knee, cell characterisation and banking method. None of them is a trial of the Golden Vial programme, and none should be read as evidence that it reverses biological age.
What the record does establish is who stands behind the protocol: a laboratory with granted patents in three jurisdictions, published clinical work in peer-reviewed journals, and standing in the field the programme draws on. That is a reason to take the science seriously. It is not the same as proof, and we are not going to present it as such.
Evidence for the programme itself is the thing we build with you, and it is the reason nothing starts before a measurement: your baseline panel, and the same panel run again afterwards. The distance between those two reports is yours — not a brochure’s.